Reply to comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia

Cancer

Volumn 116, Issue 12, 2010, Pages 3073-3074

  Heaney, Mark L ^a   Toy, Edmond L ^b   Vekeman, Francis ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Analysis Group Inc   (United States)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

CANCER CHEMOTHERAPY; FEBRILE NEUTROPENIA; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INCIDENCE; LETTER; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 77954008276     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25249     Document Type: Letter

References (3)

1. Heaney ML, Toy EL, Vekeman F, et al. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer. 2009;115:4839-4848.
2. Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. 2003;20:54-60.
3. Olson CM, Cummings P, Rivara FP. Association of first- and second-generation air bags with front occupant death in car crashes: a matched cohort study. Am J Epidemiol. 2006;164: 161-169. (Pubitemid 43992182)